Cancer Biomarker Market: By Biomarker Type (Protein Biomarker, Genetic Biomarker, Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Non-Hodgkin's Lymphoma, Bladder Cancer, Kidney Cancer, Liver Cancer, Others), By Profiling Technology (OMICS Technology, Imaging Technology, Immunoassays, Cytogenetics, Bioinformatics, Others), By Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Others), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Cancer Biomarker Market size was valued at USD 15.06 billion in 2022 and expected to reach USD 31.53 billion by 2029 witnessing a CAGR rate of 11.5% from 2023-2029. For instance, according to WHO 2018 data, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, a rise in R&D for the development of newer biomarkers, rise in funding from public and private sectors, an increase in the adoption of cancer biomarkers for drug discovery and development, and a surge in demand for early-stage disease diagnosis are expected to propel the market over the forecast years. However, stringent regulations for product approval, high costs for the R&D, and lack of favorable reimbursement guidelines are hampering the growth of the market over the forecast years. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.

Global Cancer Biomarker Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

11.5%

Largest Market

North America

Fastest Growing Market

Asia-Pacific
Cancer Biomarker Market Dynamics

Increase in the R&D for the development of newer products is a major factor drive the global cancer biomarker market over the forecast years. For instance, in May 2019, Roche Diagnostics launched HER2 biomarker that can detect the breast and gastric cancer. Moreover, raise in funding for R&D also boost the market over the forecast timeframe. For instance, in March 2016, The National Cancer Institute has reserved $5.5 million in 2016 to fund the establishment of laboratories to advance research on biomarkers and biomarker assays for cancers of the breast, prostate, lung, and genitourinary organs.

Global Cancer Biomarker Market Segmentation

By Biomarker Type
  • Protein Biomarker
  • Genetic Biomarker
  • Others
By Cancer Type
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Non-Hodgkin's Lymphoma
  • Bladder Cancer
  • Kidney Cancer
  • Liver Cancer
  • Others
By Application
  • Diagnostics
  • Drug Discovery and Development
  • Prognostics
  • Risk Assessment
  • Others
By Profiling Technology
  • OMICS Technology
  • Imaging Technology
  • Immunoassays
  • Cytogenetics
  • Bioinformatics
  • Others

Frequently Asked Questions

The cancer biomarker market size was valued at USD 15.06 billion in 2022.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • Global cancer biomarker market expanding at significant CAGR over 2023 to 2029 owing to increase in the prevalence of cancer disease.
  • Based on biomarker type, protein biomarker accounted for larger market revenue share in 2022 and projected gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global cancer biomarker market
1. Executive Summary
2. Global Cancer Biomarker Market Introduction 
2.1.Global Cancer Biomarker Market  - Taxonomy
2.2.Global Cancer Biomarker Market  - Definitions
2.2.1.Biomarker Type
2.2.2.Cancer Type
2.2.3.Application
2.2.4.Profiling Technology
2.2.5.Region
3. Global Cancer Biomarker Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Cancer Biomarker Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Cancer Biomarker Market  By Biomarker Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Protein Biomarker
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Genetic Biomarker
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Others
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6. Global Cancer Biomarker Market  By Cancer Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Breast Cancer
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Lung Cancer
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Prostate Cancer
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Non-Hodgkin's Lymphoma
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Bladder Cancer
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Kidney Cancer
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. Liver Cancer
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
6.8. Others
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.8.3. Market Opportunity Analysis 
7. Global Cancer Biomarker Market  By Application, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Diagnostics
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Drug Discovery and Development
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Prognostics
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Risk Assessment
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Others
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8. Global Cancer Biomarker Market  By Profiling Technology, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. OMICS Technology
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Imaging Technology
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Immunoassays
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Cytogenetics
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Bioinformatics
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
8.6. Others
8.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.6.3. Market Opportunity Analysis 
9. Global Cancer Biomarker Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10. North America Cancer Biomarker Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Biomarker Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Protein Biomarker
10.1.2.Genetic Biomarker
10.1.3.Others
10.2.  Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Breast Cancer
10.2.2.Lung Cancer
10.2.3.Prostate Cancer
10.2.4.Non-Hodgkin's Lymphoma
10.2.5.Bladder Cancer
10.2.6.Kidney Cancer
10.2.7.Liver Cancer
10.2.8.Others
10.3.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Diagnostics
10.3.2.Drug Discovery and Development
10.3.3.Prognostics
10.3.4.Risk Assessment
10.3.5.Others
10.4.  Profiling Technology Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.OMICS Technology
10.4.2.Imaging Technology
10.4.3.Immunoassays
10.4.4.Cytogenetics
10.4.5.Bioinformatics
10.4.6.Others
10.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11. Europe Cancer Biomarker Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Biomarker Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Protein Biomarker
11.1.2.Genetic Biomarker
11.1.3.Others
11.2.  Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Breast Cancer
11.2.2.Lung Cancer
11.2.3.Prostate Cancer
11.2.4.Non-Hodgkin's Lymphoma
11.2.5.Bladder Cancer
11.2.6.Kidney Cancer
11.2.7.Liver Cancer
11.2.8.Others
11.3.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Diagnostics
11.3.2.Drug Discovery and Development
11.3.3.Prognostics
11.3.4.Risk Assessment
11.3.5.Others
11.4.  Profiling Technology Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.OMICS Technology
11.4.2.Imaging Technology
11.4.3.Immunoassays
11.4.4.Cytogenetics
11.4.5.Bioinformatics
11.4.6.Others
11.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12. Asia Pacific (APAC) Cancer Biomarker Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Biomarker Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Protein Biomarker
12.1.2.Genetic Biomarker
12.1.3.Others
12.2.  Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Breast Cancer
12.2.2.Lung Cancer
12.2.3.Prostate Cancer
12.2.4.Non-Hodgkin's Lymphoma
12.2.5.Bladder Cancer
12.2.6.Kidney Cancer
12.2.7.Liver Cancer
12.2.8.Others
12.3.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Diagnostics
12.3.2.Drug Discovery and Development
12.3.3.Prognostics
12.3.4.Risk Assessment
12.3.5.Others
12.4.  Profiling Technology Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.OMICS Technology
12.4.2.Imaging Technology
12.4.3.Immunoassays
12.4.4.Cytogenetics
12.4.5.Bioinformatics
12.4.6.Others
12.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13. Middle East and Africa (MEA) Cancer Biomarker Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Biomarker Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Protein Biomarker
13.1.2.Genetic Biomarker
13.1.3.Others
13.2.  Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Breast Cancer
13.2.2.Lung Cancer
13.2.3.Prostate Cancer
13.2.4.Non-Hodgkin's Lymphoma
13.2.5.Bladder Cancer
13.2.6.Kidney Cancer
13.2.7.Liver Cancer
13.2.8.Others
13.3.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Diagnostics
13.3.2.Drug Discovery and Development
13.3.3.Prognostics
13.3.4.Risk Assessment
13.3.5.Others
13.4.  Profiling Technology Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.OMICS Technology
13.4.2.Imaging Technology
13.4.3.Immunoassays
13.4.4.Cytogenetics
13.4.5.Bioinformatics
13.4.6.Others
13.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14. Latin America Cancer Biomarker Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
14.1. Biomarker Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Protein Biomarker
14.1.2.Genetic Biomarker
14.1.3.Others
14.2.  Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Breast Cancer
14.2.2.Lung Cancer
14.2.3.Prostate Cancer
14.2.4.Non-Hodgkin's Lymphoma
14.2.5.Bladder Cancer
14.2.6.Kidney Cancer
14.2.7.Liver Cancer
14.2.8.Others
14.3.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Diagnostics
14.3.2.Drug Discovery and Development
14.3.3.Prognostics
14.3.4.Risk Assessment
14.3.5.Others
14.4.  Profiling Technology Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.OMICS Technology
14.4.2.Imaging Technology
14.4.3.Immunoassays
14.4.4.Cytogenetics
14.4.5.Bioinformatics
14.4.6.Others
14.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Thermo Fisher Scientific, Inc.
15.2.2.Illumina, Inc.
15.2.3.Hoffmann La Roche Ltd.
15.2.4.Hologic, Inc.
15.2.5.Creative Diagnostics
15.2.6.Quest Diagnostics
15.2.7.Bio-Rad Laboratories Inc.
15.2.8.Abbott Laboratories
15.2.9.Exact Sciences
15.2.10.Meso Scale Diagnostics LLC
15.2.11.Seegene Technologies Inc.
15.2.12.Siemens Healthineers
16. Research Methodology 
17. Appendix and Abbreviations 
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Hoffmann La Roche Ltd.
  • Hologic, Inc.
  • Creative Diagnostics
  • Quest Diagnostics
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Exact Sciences
  • Meso Scale Diagnostics LLC
  • Seegene Technologies Inc.
  • Siemens Healthineers

Adjacent Markets